Latest news and articles about BMS
Total: 1 articles found
Chinese biotech firm Bioken has reported record-breaking Phase II clinical results for its bispecific ADC lung cancer treatment, achieving a 100% tumor shrinkage rate in target lesions. Backed by a historic $8.4 billion deal with Bristol Myers Squibb, the company’s success highlights China’s rapid ascent from a generic drug producer to a leader in original pharmaceutical innovation.
